Dermatology · 2007 · 34 citations · 13 references
MedicineDermatologyImmunologyAutoimmunityImmunopathologyMonoclonal AntibodiesAutoimmune Blistering DiseasesAutoimmune DiseasesAutoimmune Skin DiseasesEpidermolysis BullosaImmunosuppressionInflammatory DermatosesAnti-cd20 Antibody TherapyAnti-cd20 TherapyAutoimmune Blistering DermatosesAutoimmune Skin Blistering DisordersAutoimmune Subepidermal Blistering DiseasesBullous DermatosesImmunological ResponseSubepidermal Blistering Disorders
Epidermolysis bullosa acquisita is a rare autoimmune subepidermal blistering disease, often resisting current treatments, especially systemic corticosteroids. We report a patient having a bullous pemphigoid who relapsed with clinical and immunological features of inflammatory epidermolysis bullosa acquisita. An anti-CD20 monoclonal antibody (rituximab) was proposed because of resistance to high-dose steroids and other immunosuppressive agents. The disease dramatically improved within a few weeks following rituximab infusion allowing the decrease in steroid therapy. Our case illustrates also the possible evolution from bullous pemphigoid to epidermolysis bullosa acquisita that should be suspected when clinical atypia occurs or in case of corticosteroid resistance.
13
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
Meral J. Arin, Andreas Engert, Thomas Krieg et al. · British Journal of Dermatology · 2005 · 145 citations